Pharmacology Flashcards
First line treatment for tonic-clonic seizures
Phenytoin/fosphenytoin or valproic acid
First line treatment for absence seizures
Ethosuximide
First line treatment for acute status epilepticus
Benzodiazepines
First line treatment for prophylaxis of status epilepticus
Phenytoin/fosphenytoin
Antiseizure not indicated for partial seizures
Ethosuximide
First line treatment for partial seizures
Carbamazepine
Drugs indicated for absence seizures
Ethosuximide, valproic acid, lamotrigine
Side effect of lamotrigine
Steven-Johnson syndrome
Antiepileptic with zero-order kinetics
Phenytoin/fosphenytoin
Antiepileptic that is first-line in neonates
Phenobarbital
Antiepileptics that induce P450
Phenobarbital, Carbamazepine, Phenytoin/fosphenytoin (PCP)
Antiepileptics that block T-type calcium channels
Ethosuximide, Gabapentin
Antiepileptics that block sodium channels
Topiramate, Lamotrigine, Carbamazepine, Valproic acid, Phenytoin/fosphenytoin
Antiepileptics that inhibits the release of glutamate
Lamotrigine via blocking of sodium channels
Antiepileptics that causes agranulocytosis
Carbamazepine
Antiepileptics that gingival hyperplasia
Phenytoin/fosphenytoin
Barbiturate indications
Anxiety, seizures, insomnia, anesthesia induction
Barbiturates
Have suffix -barbital except thiopental
Barbiturate used for anesthesia induction
Thiopental
Barbiturates MOA
Increase duration of chloride channel opening
Contraindication for barbiturates
Porphyrias
Short-acting benzos
ATOM: Alprazolam Triazolam Oxazepam Midazolam
Long-acting benzos
Diazepam, lorazepam, temazepam, chlordiazepoxide
Benzos MOA
Increase frequency of chloride channel
Benzos indicated for status epilepticus
Diazepam and lorazepam
Benzos overdose treatment
Flumazenil
Non-benzos hypnotics
Zolpidem, Zaleplon, esZopiclone (all ZZZs put to sleep)
Non-benzos hypnotics effects reversed by what drug
Flumazenil
Suvorexant MOA
Orexin receptor antagonist
Suvorexant indications
Insomnia
Suvorexant contraindications
Narcolepsy, liver disease, and with strong CYP3A4 inhibitors
Ramelteon MOA
Melatonin receptor antagonist, binds MT1 and MT2 in suprachiasmatic nucleus
Ramelteon indications
Insomnia
Triptans MOA
5-HT1b/1d agonist
Inhibit trigeminal nerve activation
Prevent vasoactive peptide release
Induce vasoconstriction
Triptans indications
Acute migraine, cluster headache attacks
Triptans contraindications
CAD and Prinzmetal angina
Triptans side-effects
Serotonin syndrome with other 5-HT agonist
Cause of parkinsonism
Loss of dopaminergic neurons and excess cholinergic activity
Amantadine MOA
Increase dopamine release, inhibit reuptake
Amantadine toxicity
Ataxia, livedo reticularis
Carbidopa MOA
Blocks peripheral conversion of L-DOPA increasing dopamine by blocking DOPA decarboxylase
Entacapone, tolcapone
Inhibit COMT preventing peripheral L-DOPA degradation to 3-OMD
Selegiline
Blocks MAO-B preventing conversion of dopamine to DOPAC
Tolcapone
Blocks COMT preventing conversion of dopamine to 3-MT